Tenax Therapeutics Inc is dedicated to upholding core values and a strong corporate philosophy. They prioritize innovation, patient care, and scientific excellence in the field of biopharmaceuticals. The company aims to develop groundbreaking therapies to address crucial unmet needs within the healthcare industry. Tenax Therapeutics Inc values transparency, integrity, and collaboration, fostering relationships with key stakeholders and industry experts. By implementing cutting-edge research and development strategies, the company strives to bring novel treatment options to patients and improve their quality of life. Tenax Therapeutics Inc is committed to making a positive impact on the healthcare landscape and enhancing the overall well-being of their patients.

Tenax Therapeutics Inc is primarily present in the United States.

Tenax Therapeutics Inc has achieved several significant milestones in its trajectory. One notable accomplishment is the successful completion of a Phase 3 clinical trial for their lead product candidate, Levosimendan. The trial demonstrated positive results in treating patients with pulmonary hypertension associated with heart failure. Additionally, Tenax Therapeutics Inc has secured FDA fast track designation for Levosimendan, recognizing its potential to address an unmet medical need. These milestones signify Tenax Therapeutics Inc's commitment to advancing innovative solutions in cardiovascular and pulmonary diseases, solidifying their position as a key player in the industry.

Tenax Therapeutics Inc. is a pharmaceutical company with a rich history and background. Founded in 1967, Tenax has been dedicated to developing innovative therapies to address unmet medical needs. With headquarters in Morrisville, North Carolina, the company focuses on the discovery and commercialization of small molecule compounds for the treatment of cardiovascular diseases and other related conditions. Tenax has built a strong reputation for its cutting-edge research and commitment to patient health. Leveraging its expertise in drug formulation and clinical development, Tenax Therapeutics Inc. continues to strive towards improving the lives of patients worldwide.

Some of the main competitors of Tenax Therapeutics Inc in the market include companies like Athersys, Inc., BioCardia, Inc., and CryoLife, Inc. These companies also operate in the biotechnology or pharmaceutical industries and compete with Tenax Therapeutics Inc to develop innovative therapies and treatments.

Tenax Therapeutics Inc primarily operates in the healthcare and pharmaceutical industries.

The business model of Tenax Therapeutics Inc is focused on developing and commercializing pharmaceutical products for critical care patients. The company primarily focuses on addressing acute-care conditions with limited therapeutic options. Tenax Therapeutics Inc aims to provide innovative and effective solutions for patients in need of urgent medical intervention. With a strong emphasis on research and development, the company strives to bring novel therapies to market that can improve the lives of individuals facing life-threatening conditions. Tenax Therapeutics Inc is committed to advancing the field of critical care medicine through its dedicated efforts and expertise.

Το Tenax Therapeutics P/E είναι -0,04.

Το KUV της εταιρείας Tenax Therapeutics είναι 0.

Το AlleAktien Qualitätsscore για το Tenax Therapeutics είναι 2/10.

Τα έσοδα δεν μπορούν να υπολογιστούν επί του παρόντος για Tenax Therapeutics.

Το αναμενόμενη Tenax Therapeutics κέρδος είναι -23,23 Εκ. USD.

Tenax Therapeutics Inc is a biopharmaceutical company specializing in the development and marketing of products for the treatment of heart and lung diseases. The company was founded in 1967 and is based in Morrisville, North Carolina. The main business of Tenax Therapeutics is the development of therapeutic products for the treatment of cardiovascular and pulmonary diseases. The company has two main products in the pipeline, both in clinical development: - Levosimendan: Levosimendan is an intravenously administered medication used for the treatment of patients with acute heart failure. The medication has already been approved in Europe and other countries and is currently being tested in a Phase 3 study in the United States. - Brensocatib: Brensocatib is an oral medication developed for the treatment of patients with chronic obstructive pulmonary disease (COPD). The medication shows promising results in clinical development and is expected to be approved in the coming years. Tenax Therapeutics also has a subsidiary called LifeAgain Insurance Solutions, specializing in the marketing of life insurance. However, this division of the company is not the core business and contributes only a small part to the revenue. The business model of Tenax Therapeutics is based on the development and marketing of innovative and successful medications for the treatment of cardiovascular and pulmonary diseases. The company works closely with academic research institutions and suppliers to accelerate the development of new products and advance scientific progress in this field. Tenax Therapeutics aims to sell and distribute its products worldwide to increase its revenue and expand its market presence. The company also intends to build long-term partnerships with other companies and organizations in the healthcare industry to expand its product pipeline and create new opportunities for research and development in the field of cardiovascular and pulmonary diseases. In summary, Tenax Therapeutics Inc is a leading company in the research and development of medications for the treatment of cardiovascular and pulmonary diseases. The company aims to sell its products worldwide and build long-term partnerships with other companies and organizations in the healthcare industry to expand its product pipeline and advance research in the field of cardiovascular and pulmonary diseases.

Η Tenax Therapeutics καταβάλλει μια διανομή της τάξεως των 0 USD διαμοιρασμένη σε δόσεις ετησίως.

Το μέρισμα δεν μπορεί να υπολογιστεί για το Tenax Therapeutics αυτή τη στιγμή ή η εταιρεία δεν διανέμει μέρισμα.

Ο αριθμός ISIN της Tenax Therapeutics είναι US88032L2097.

Το WKN της Tenax Therapeutics είναι A2JEYS.

Ο τίκερ της Tenax Therapeutics είναι TENX.

Κατά τους τελευταίους 12 μήνες η Tenax Therapeutics κατέβαλε μια μέρισμα ύψους . Αυτό αντιστοιχεί σε απόδοση μερίσματος περίπου . Για τους επόμενους 12 μήνες, η Tenax Therapeutics προβλέπεται να πληρώσει μέρισμα 0 USD.

Η απόδοση μερίσματος της Tenax Therapeutics ανέρχεται σήμερα στο .

Tenax Therapeutics πληρώνει τέταρτον διανεμητέου μισθό. Αυτή καταβάλλεται τους μήνες .

Η Tenax Therapeutics πλήρωσε κάθε χρόνο μέρισμα μέσα στα τελευταία 0 έτη.

Για τους επόμενους 12 μήνες αναμένονται μερίσματα σε ύψος των 0 USD. Αυτό αντιστοιχεί σε απόδοση μερίσματος 0 %.

Το Tenax Therapeutics ανατίθεται στον τομέα 'Υγεία'.

Για να λάβεις το τελευταίο μέρισμα των Tenax Therapeutics από την 22/9/2024 με τιμή 0 USD, έπρεπε να έχεις τη μετοχή στο χαρτοφυλάκιο σου πριν από την ημέρα Ex-Tag στις 22/9/2024.

Η τελευταία μερίσματος έγινε στις 22/9/2024.

Το έτος 2023, η Tenax Therapeutics διένειμε 0 USD ως μερίσματα.

Τα μερίσματα του Tenax Therapeutics καταβάλλονται σε USD.